A report published by the Cell & Gene Collective, based on the findings of an expert commission, has offered recommendations to ensure the UK’s leadership in cell and gene therapies (CGTs) and urgently remove barriers to their adoption.
The Cell & Gene Collective is an alliance of biopharma companies with an interest in CGTs. Member companies are Bayer (BAYN: DE), Johnson & Johnson (NYSE: JNJ), Gilead Sciences (Nasdaq: GILD), Orchard Therapeutics (Nasdaq: ORTX) and Vertex Pharmaceuticals (Nasdaq: VRTX).
Its report, entitled Tomorrow’s Science, Today’s National Health Service (NHS): Unleashing a new era of medicine, makes 25 immediate and medium-term recommendations to foster UK leadership in the sector, build strong foundations to improve access, and realize a new era of medicine.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze